The Latest Cardiac and Vascular News
CARLSBAD, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on April 1, 2023 that were approved by the Compensation Committee of its Board of […]
SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of 57,600 shares of common stock to 4 new employees, whose employment commenced in March 2023, as a material inducement to […]
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 million in the fourth quarter of 2022 (91% growth […]
EDEN PRARIE, MN, April 03, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. “We are very pleased with the […]
WARRINGTON, Pa., April 03, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided key business updates. “We continued to advance our cardiovascular […]
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China Strengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. […]
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced financial results for the fourth quarter and full year ended December 31, 2022. Company Updates Announced the progression of its […]
PONTE VEDRA, Fla., March 30, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, […]
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth […]
Progress continued on the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Expanded intellectual property portfolio with four issued patents in 2022 Management team strengthened and expanded in 2022 Sufficiently funded into second half of 2025 WALTHAM, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Aerovate […]
